Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
Feld JJ, Forns X, Dylla DE, Kumada H, de Ledinghen V, Wei L, Brown RS Jr, Flisiak R, Lampertico P, Thabut D, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Jacobson IM. Feld JJ, et al. Among authors: dylla de. J Viral Hepat. 2022 Dec;29(12):1050-1061. doi: 10.1111/jvh.13738. Epub 2022 Oct 6. J Viral Hepat. 2022. PMID: 36036117 Free PMC article.
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M, Puoti M, Caruntu F, Slim J, Nevens F, Sigal S, Cohen S, Fredrick LM, Pires Dos Santos AG, Rodrigues L Jr, Dillon JF. Zuckerman E, et al. Among authors: dylla de. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2544-2553.e6. doi: 10.1016/j.cgh.2020.06.044. Epub 2020 Jul 1. Clin Gastroenterol Hepatol. 2020. PMID: 32621971 Free article.
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Forns X, Feld JJ, Dylla DE, Pol S, Chayama K, Hou J, Heo J, Lampertico P, Brown A, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Gordon SC, Jacobson IM. Forns X, et al. Among authors: dylla de. Adv Ther. 2021 Jun;38(6):3409-3426. doi: 10.1007/s12325-021-01753-3. Epub 2021 May 22. Adv Ther. 2021. PMID: 34021887 Free PMC article.
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Gane E, de Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, Calleja JL, Xue Z, Burroughs M, Gutierrez JA. Gane E, et al. Among authors: dylla de. J Viral Hepat. 2021 Nov;28(11):1635-1642. doi: 10.1111/jvh.13600. Epub 2021 Sep 8. J Viral Hepat. 2021. PMID: 34448313 Free PMC article. Clinical Trial.
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Zamor PJ, Brown A, Dylla DE, Dillon JF, Luetkemeyer AF, Feld JJ, Mutimer D, Ghalib R, Crown E, Lovell SS, Hu Y, Moreno C, Nelson DR, Colombo M, Papatheodoridis G, Rockstroh JK, Skoien R, Lawitz E, Jacobson IM. Zamor PJ, et al. Among authors: dylla de. Am J Gastroenterol. 2021 Sep 1;116(9):1896-1904. doi: 10.14309/ajg.0000000000001332. Am J Gastroenterol. 2021. PMID: 34465693 Free PMC article.
Assessment of Drug-Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations.
Mukherjee D, Collins M, Dylla DE, Kaur J, Semizarov D, Martinez A, Conway B, Khan T, Mostafa NM. Mukherjee D, et al. Among authors: dylla de. Infect Dis Ther. 2023 Aug;12(8):2057-2070. doi: 10.1007/s40121-023-00830-0. Epub 2023 Jul 20. Infect Dis Ther. 2023. PMID: 37470926 Free PMC article.
16 results